HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Acute coronary insufficiency — Clinical Guidelines

Overview

Acute coronary insufficiency encompasses conditions like unstable angina and acute myocardial infarction, characterized by inadequate blood supply to the heart muscle due to coronary artery obstruction. 1

Diagnosis

Clinical Presentation: Chest pain, shortness of breath, nausea, sweating.

Electrocardiogram (ECG): ST-segment changes, T-wave inversions indicative of ischemia.

Cardiac Biomarkers: Elevated troponin levels confirm myocardial injury.

Coronary Angiography: Visualizes coronary artery blockages.

Risk Factor Assessment: Evaluate smoking history, lipid profile, hypertension, diabetes. 1

Management

Antiplatelet Therapy: Aspirin (loading dose 300 mg) and P2Y12 inhibitor (e.g., clopidogrel, ticagrelor).

Anticoagulation: Heparin or low molecular weight heparin for acute phase.

Beta-Blockers: Reduce myocardial oxygen demand (e.g., metoprolol, bisoprolol).

ACE Inhibitors/ARBs: For patients with left ventricular dysfunction or hypertension (e.g., lisinopril, losartan).

Statins: To lower cholesterol and stabilize plaques (e.g., atorvastatin, simvastatin).

Revascularization: Consider PCI or CABG for significant stenosis or recurrent symptoms. 2

Special Populations

Smoking Cessation: Ex-smokers remain at higher risk for at least 15 years post-cessation; risk profile approaches non-smokers after 15 years. (Evidence: Moderate) 1

Comorbidities: Elevated triglycerides correlate with increased FVII-phospholipid complex in acute coronary events, suggesting a role in management strategies targeting lipid control. (Evidence: Moderate) 2

Key Recommendations

Assess and manage smoking cessation aggressively, recognizing residual risk persists for at least 15 years post-cessation before risk profiles normalize compared to non-smokers. (Evidence: Moderate) 1

Monitor and manage lipid levels, particularly triglycerides, given their association with coagulation factor VII activity in acute coronary events. (Evidence: Moderate) 2

Implement early antiplatelet therapy and anticoagulation in acute coronary insufficiency to prevent further thrombotic events. (Evidence: Expert opinion) 2

References

1 Robinson K, Conroy RM, Mulcahy R. When does the risk of acute coronary heart disease in ex-smokers fall to that in non-smokers? A retrospective study of patients admitted to hospital with a first episode of myocardial infarction or unstable angina. British heart journal 1989. link 2 Sandset PM, Sirnes PA, Abildgaard U. Factor VII and extrinsic pathway inhibitor in acute coronary disease. British journal of haematology 1989. link

Acute coronary insufficiency